Association of Sacubitril/Valsartan versus Valsartan with Blood Pressure Changes, and Symptomatic Hypotension: The PARAGLIDE-HF Trial
Fudim M, Cyr D, Ward J, Hernandez A, Lepage S, Morrow D, Sharma K, Claggett B, Starling R, Velazquez E, Williamson K, Desai A, Zieroth S, Solomon S, Braunwald E, Mentz R, Investigators P. Association of Sacubitril/Valsartan versus Valsartan with Blood Pressure Changes, and Symptomatic Hypotension: The PARAGLIDE-HF Trial. Journal Of Cardiac Failure 2024 PMID: 38802053, DOI: 10.1016/j.cardfail.2024.04.030.Peer-Reviewed Original ResearchLeft ventricular ejection fractionWorsening heart failureBaseline systolic blood pressureSystolic blood pressureVentricular ejection fractionEjection fractionSymptomatic hypotensionNT-proBNPHeart failureBlood pressureLow baseline systolic blood pressureTime-averaged proportional changeMildly reduced ejection fractionPlasma NT-proBNP levelsAssociated with clinical benefitB-type natriuretic peptideNT-proBNP levelsReduced ejection fractionMedian blood pressureBlood pressure changesSH eventsTime-averaged changePrimary endpointNatriuretic peptideRandomized patientsSacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure
Morrow D, Velazquez E, Desai A, DeVore A, Lepage S, Park J, Sharma K, Solomon S, Starling R, Ward J, Williamson K, Zieroth S, Hernandez A, Mentz R, Braunwald E. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure. Journal Of The American College Of Cardiology 2024, 83: 1123-1132. PMID: 38508844, DOI: 10.1016/j.jacc.2024.01.027.Peer-Reviewed Original ResearchConceptsWorsening heart failureHeart failureEjection fractionNT-proBNPSpectrum of EFPIONEER-HFSpectrum of left ventricular ejection fractionRandomized trialsTime-averaged proportional changeN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideLeft ventricular ejection fractionWorsening heart failure eventDecompensated heart failureVentricular ejection fractionPlasma NT-proBNPPIONEER-HF trialDouble-blindMedian ageMedian EFSNatriuretic peptideSymptomatic hypotensionBaseline characteristicsClinical outcomesPooled analysis